Back to research

Research paper

Delayed forebrain excitatory and inhibitory neurogenesis in STRADA-related megalencephaly via mTOR hyperactivity

Stem Cell Reports 2026 study using patient-derived iPSC models to interrogate STRADA mutations in megalencephaly. Maps molecular consequences through the LKB1-mTOR axis.

Indexed context

Pan Y, et al.

stradamegalencephalymtorlkb1ipsc2026

Markdown path

content/research/papers/2026-pan-strada-megalencephaly-stem-cell-reports.md

Findings

Stem Cell Reports 2026 study using patient-derived iPSC models to interrogate STRADA mutations in megalencephaly. Maps molecular consequences through the LKB1-mTOR axis.

Why it may matter for Levi

STRADA is a less-common mTORopathy gene. Not currently on Levi's differential top-tier but supports the broader case that multiple less-common genes converge on the PI3K-AKT-mTOR axis - reinforcing the case for a mosaic-sensitive PROS panel rather than a single-gene test.

Paper text

Pan et al. (2026) — STRADA deficiency, megalencephaly, and mTOR hyperactivity

Source

  • Stem Cell Reports, 2026.

Why in corpus

Mechanistic study of STRADA deficiency (cause of polyhydramnios-megalencephaly-symptomatic-epilepsy / PMSE) demonstrating that mTOR hyperactivity drives delayed forebrain excitatory and inhibitory neurogenesis — and that rapamycin during fetal brain development rescues most phenotypes.

Key findings

  • STRADA deficiency → mTOR hyperactivity → delayed forebrain excitatory and inhibitory neurogenesis.
  • Rapamycin during fetal brain development rescues most phenotypes.
  • Further support for mTOR pathway as primary therapeutic target in megalencephaly-epilepsy syndromes.

Levi-relevant takeaways

  • STRADA itself is a low-prior candidate for Levi (PMSE is an Amish-enriched founder variant), but mechanistically relevant to the broader mTORopathy framework.
  • Reinforces the pattern: diverse upstream lesions (PTEN, TSC1/2, STRADA, RHEB, MTOR) converge on mTOR hyperactivity, and rapamycin can rescue across the family — supporting the treatment rationale if any mTOR-axis variant is identified in Levi.
  • Supports the overall framing: overgrowth + epilepsy + developmental delay is an mTORopathy-consistent pattern regardless of specific gene.
  • The fetal-rescue finding is developmentally relevant but not actionable for Levi (already 5.5 years); reinforces urgency of early diagnosis in any future affected sibling.